CD19 and neoplasm: Neither ZA nor NZ, alone and in combination with doxorubicin, modified the amount of intra-tumor CD19+, CD4+ or CD8+ cells (Supplementary Figure 6), suggesting that they did not affect the amount of B- and T-lymphocytes infiltrating the tumor bulk.